Terminated PHASE2 INTERVENTIONAL 1-arm NCT00005097

Green Tea Extract in Treating Patients With Actinic Keratosis

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Polyphenon E Against Various Endpoints of Actinic Keratosis Pathobiology

Sponsor: Frank Meyskens

Conditions Non-melanomatous Skin Cancer

Interventions Polyphenon E and Placebo

Updated 6 times since 2017 Last updated: Apr 3, 2018 Started: Aug 31, 1999 Primary completion: Aug 31, 2002 Completion: Aug 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

terminated due to the low conditional power for a positive study

Other Non-melanomatous Skin Cancer trials with similar outcome

Browse all Non-melanomatous Skin Cancer trials

This PHASE2 trial investigates Non-melanomatous Skin Cancer and is currently terminated or withdrawn. Frank Meyskens leads this study, which shows 6 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
May 2018 — Jun 2018 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — May 2018 [monthly]

Terminated PHASE2

First recorded

Aug 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Frank Meyskens
National Cancer Institute (NCI)

Data source: University of California, Irvine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Orange, United States